September 2003
Worldwide Biotech;Sep2003, Vol. 15 Issue 9, p4
Trade Publication
Reports on the effect of the trial success of ThromboView, a blood clot diagnostic product from Agenix Ltd., on its registration as a commercial product in the U.S.


Related Articles

  • FDA clot device advisory tells of patients' risks. Tanner, Lindsey // Adirondack Daily Enterprise;8/14/2010, Vol. 117 Issue 192, pA8 

    The article presents a report on the life-threatening problems of medical filters that block blood clots to reach the lungs for patients.

  • DO COMPRESSION STOCKINGS PROEVENT DVT ON AIRLINES?  // Pulse;6/1/2006, Vol. 66 Issue 22, p29 

    The article assesses the effects of wearing compression stockings among people who travel on airline flights for at least four hours. There has been increasing interest on whether the compression stockings, which are also called flight socks, can actually lessen the risk of deep vein thrombosis...

  • Antidote. Siegel, Marc // Medical Marketing & Media;Jan2010, Vol. 45 Issue 1, p10 

    The article reports that the U.S. Food and Drug Administration (FDA) has warned against the use of Prilosec in combination with anti-clotting drug Plavix. It mentions that on theoretical reason behind the notice is that when patients take both drugs, Plavix's ability to stop blood clot from...

  • PRODUCT BRIEFS.  // Medical Device Daily;7/9/2007, Vol. 11 Issue 130, p9 

    The article evaluates several medical devices including Dynatron X5 soft tissue oscillation therapy unit from Dynatronics, the next-generation D-dimer coagulation test, Innovance D-dimer test from the International Society on Thrombosis and Haemostasis and Dade Behring and the Physician Quality...

  • Self-healing Polymers and Composites. White, Scott R.; Blaiszik, Benjamin J.; Kramer, Sharlotte L. B.; Olugebefola, Solar C.; Moore, Jeffrey S.; Sottos, Nancy R. // American Scientist;Sep/Oct2011, Vol. 99 Issue 5, p392 

    The article focuses on self-healing polymers and fiber-reinforced composites. It explores the principles for synthetic healing of these materials that mimic the process in biological systems, such as inflammation and blood clotting and the ensuing regrowth of new tissue to the injured area. It...

  • Replenine-VF.  // Royal Society of Medicine: Medicines;2002, p472 

    This article presents information on replenine-VF, a proprietary, prescription-only preparation of factor IX fraction, dried, which is prepared from human blood plasma. It can be used in treating patients with a deficiency in factor IX, and is available in a form for intravenous infusion.

  • Recombinant Clotting Factors: A Review of Current Clinical Status. Lusher, J.M. // BioDrugs;2000, Vol. 13 Issue 4, p289 

    In the short time span since the cloning of the human genes for factors VIII, IX and VII, recombinant factor (rF)VIII, rFIX and rFVIIa concentrates have been produced and standardised, have entered clinical trials, and have been licensed for clinical use in the US, Europe and elsewhere. Even...

  • Clotting problems raise risk of SWL complications. Dahm, Philipp // Urology Times;Jun2001, Vol. 29 Issue 6, p16 

    Reports on findings of a study from the University of Vienna in Austria, which showed that patients with known coagulopathy who are treated for stones have increased risk of complications despite normal clotting parameters. Link of endourologic procedures with the lowest rate of complications;...

  • Roche Acquires Verum Diagnostica GmbH.  // Worldwide Biotech;Jan2012, Vol. 24 Issue 1, p1 

    The article reports on the acquisition of Verum Diagnostica GmbhH, a company based in Munich, Germany involved in the coagulation diagnostics market by Roche. The acquisition is in line with the plans of Roche to expand its coagulation testing product line in North America. The amount that Roche...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics